Literature DB >> 29397015

Differential virus-specific CD8+ T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.

Hendrik Luxenburger1, Franziska Graß1, Janina Baermann1, Tobias Boettler1, Matthias Marget2, Florian Emmerich3, Marcus Panning4, Robert Thimme1, Katja Nitschke1, Christoph Neumann-Haefelin1.   

Abstract

Virus-specific CD8+ T-cell responses play an important role in the outcome of hepatitis C virus (HCV) infection. To date, most HCV-specific CD8+ T-cell epitopes have been defined in HCV genotype 1 infection. In contrast, the HCV genotype 4-specific CD8+ T-cell response is poorly defined. Here, we analysed whether known HCV-specific CD8+ T-cell epitopes are also recognized in HCV genotype 4-infected patients and set out to identify the first HCV genotype 4-specific CD8+ T-cell epitopes. We studied patients chronically infected with HCV genotype 1 (n = 20) or 4 (n = 21) using 91 well-described HCV-specific epitope peptides. In addition, we analysed 24 genotype 4-infected patients using 40 epitope candidates predicted using an in silico approach. HCV-specific CD8+ T-cell responses targeting previously described epitopes were detectable in the majority of genotype 1-infected patients (11 of 20). In contrast, patients infected with HCV genotype 4 rarely targeted these epitopes (4 of 21; P = .0247). Importantly, we were able to identify eight novel HCV genotype 4-specific CD8+ T-cell epitopes. Only one of these epitopes was shared between genotype 1 and genotype 4. These results indicate that there is little overlap between CD8+ T-cell repertoires targeting HCV genotype 1 and 4. Prophylactic vaccination studies based on HCV genotype 1 are currently underway. However, in countries with the highest prevalence of HCV infection, such as Egypt, most patients are infected with HCV genotype 4. Thus, prophylactic vaccination strategies need to be adapted to HCV genotype 4 before their application to regions where HCV genotype 4 is endemic.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD8+ T-cell response; hepatitis C virus; vaccination; viral genotypes

Mesh:

Substances:

Year:  2018        PMID: 29397015     DOI: 10.1111/jvh.12874

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  INeo-Epp: A Novel T-Cell HLA Class-I Immunogenicity or Neoantigenic Epitope Prediction Method Based on Sequence-Related Amino Acid Features.

Authors:  Guangzhi Wang; Huihui Wan; Xingxing Jian; Yuyu Li; Jian Ouyang; Xiaoxiu Tan; Yong Zhao; Yong Lin; Lu Xie
Journal:  Biomed Res Int       Date:  2020-06-15       Impact factor: 3.411

Review 2.  Hepatitis C Virus Vaccine: Challenges and Prospects.

Authors:  Joshua D Duncan; Richard A Urbanowicz; Alexander W Tarr; Jonathan K Ball
Journal:  Vaccines (Basel)       Date:  2020-02-17

Review 3.  Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.

Authors:  Rohan Janardhan Meshram; Gunderao Hanumantrao Kathwate; Rajesh Nivarti Gacche
Journal:  Arch Virol       Date:  2022-01-28       Impact factor: 2.685

Review 4.  Adaptive Immune Response against Hepatitis C Virus.

Authors:  Janine Kemming; Robert Thimme; Christoph Neumann-Haefelin
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.